Identification of Prognostic Immunophenotypes at First Diagnosis in Patients with Acute Myeloid Leukemia (AML) By a Standardized Multicolor Flow Cytometry (MFC) Panel Originally Designed to Detect Measurable Residual Disease (MRD) at Follow-up
Maximilian Alexander Röhnert(University Hospital Carl Gustav Carus), Uta Oelschlägel(University Hospital Carl Gustav Carus), Philipp Ensel(University Hospital Carl Gustav Carus), Christoph Röllig(University Hospital Carl Gustav Carus), Martin Bornhäuser(Technische Universität Dresden), Sylvie Freeman(University of Birmingham), Michael A. Rieger(Goethe University Frankfurt), Nicole Hofmeister-Mielke(Heidelberg University), Cornelia Brendel(Philipps University of Marburg), Richard F. Schlenk(German Cancer Research Center), Nadja Holtschke(University Hospital Carl Gustav Carus), Stefan W. Krause(Universitätsklinikum Erlangen), Marion Subklewe(LMU Klinikum), Jörg Hoffmann(Philipps University of Marburg), Malte von Bonin(Städtisches Klinikum Dresden), Veit Buecklein(LMU Klinikum), Tobias Berg(Goethe University Frankfurt), Simon Voelkl(Friedrich-Alexander-Universität Erlangen-Nürnberg), Michael Krämer(University Hospital Carl Gustav Carus)
Cited by 2
Related Papers
Genomic Classification and Prognosis in Acute Myeloid Leukemia
|New England Journal of Medicine|2016|4.4k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Diverse Applications of Nanomedicine
|ACS Nano|2017|1.4k